Literature DB >> 24606532

Pure laparoscopic right-sided hepatectomy in the semi-prone position for synchronous colorectal cancer with liver metastases.

Satoshi Ida1, Eiji Oki, Koji Ando, Yasue Kimura, Yo-ichi Yamashita, Hiroshi Saeki, Toru Ikegami, Tomoharu Yoshizumi, Masayuki Watanabe, Masaru Morita, Ken Shirabe, Tetsuya Kusumoto, Tetsuo Ikeda, Hideo Baba, Yoshihiko Maehara.   

Abstract

INTRODUCTION: Simultaneous resection for colorectal cancer and synchronous colorectal liver metastases (SCRLM) has been found to be safe and effective. However, pure laparoscopic simultaneous resection (PULSAR) for primary colorectal cancer and SCRLM is usually difficult, especially in the right lobe of the liver. The purpose of this study was to assess the feasibility of PULSAR for patients with primary colorectal cancer and SCRLM.
METHODS: From January 2008 to December 2012, a total of 10 patients (9 men and 1woman; mean age, 64 years) underwent PULSAR for a primary tumor and SCRLM.
RESULTS: Seven patients (70%) with lesions in the right lobe (segments 6, 7, and 8) successfully underwent resection with a pure laparoscopic procedure while in the left semi-prone position. No patient was converted to conventional open surgery. The mean operative duration, volume of bleeding, and postoperative hospital stay were 606 ± 46 min, 585 ± 145 mL, and 18 ± 3.5 days, respectively. Although a liver abscess developed in one patient, no colonic complications or perioperative death occurred.
CONCLUSION: PULSAR for primary colorectal cancer and SCRLM is a feasible multidisciplinary treatment. Moreover, PULSAR can be safely and effectively performed with the patient in the semi-prone position, even when SCRLM exists in the right lobe of the liver.
© 2014 Japan Society for Endoscopic Surgery, Asia Endosurgery Task Force and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Colorectal cancer; laparoscopy; liver metastasis

Mesh:

Year:  2014        PMID: 24606532     DOI: 10.1111/ases.12098

Source DB:  PubMed          Journal:  Asian J Endosc Surg        ISSN: 1758-5902


  4 in total

1.  The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology.

Authors:  Aldo Rocca; Federica Cipriani; Paolo Delrio; Fulvio Calise; Luca Aldrighetti; Giulio Belli; Stefano Berti; Ugo Boggi; Vincenzo Bottino; Umberto Cillo; Matteo Cescon; Matteo Cimino; Francesco Corcione; Luciano De Carlis; Maurizio Degiuli; Paolo De Paolis; Agostino Maria De Rose; Domenico D'Ugo; Fabrizio Di Benedetto; Ugo Elmore; Giorgio Ercolani; Giuseppe M Ettorre; Alessandro Ferrero; Marco Filauro; Felice Giuliante; Salvatore Gruttadauria; Alfredo Guglielmi; Francesco Izzo; Elio Jovine; Andrea Laurenzi; Francesco Marchegiani; Pierluigi Marini; Marco Massani; Vincenzo Mazzaferro; Michela Mineccia; Francesco Minni; Andrea Muratore; Simone Nicosia; Riccardo Pellicci; Riccardo Rosati; Nadia Russolillo; Antonino Spinelli; Gaya Spolverato; Guido Torzilli; Giovanni Vennarecci; Luca Viganò; Leonardo Vincenti
Journal:  Updates Surg       Date:  2021-06-05

2.  Simultaneous Pure Laparoscopic Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: A Single Institution Experience with Propensity Score Matching Analysis.

Authors:  Arpad Ivanecz; Bojan Krebs; Andraz Stozer; Tomaz Jagric; Irena Plahuta; Stojan Potrc
Journal:  Radiol Oncol       Date:  2017-11-01       Impact factor: 2.991

3.  The Value of Laparoscopic Simultaneous Colorectal and Hepatic Resection for Synchronous Colorectal Cancer Liver Metastasis: A Propensity Score Matching Study.

Authors:  Jiamin Zhou; Longhai Feng; Xinxiang Li; Miao Wang; Yiming Zhao; Ning Zhang; Longrong Wang; Ti Zhang; Anrong Mao; Ye Xu; Lu Wang
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

Review 4.  Simultaneous Minimally Invasive Treatment of Colorectal Neoplasm with Synchronous Liver Metastasis.

Authors:  Stefano Garritano; Federico Selvaggi; Marcello Giuseppe Spampinato
Journal:  Biomed Res Int       Date:  2016-05-15       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.